A product launch and a profitability update drove the headline news in health and biotech on Wednesday, with Imaging Biometrics (AIM:IBAI) rolling out its next-generation neuroimaging tool alongside a reaffirmed 2026 progress target, while Novo Nordisk made history by becoming the first company to bring an oral GLP-1 weight-loss pill to a market outside the United States.
Imaging Biometrics reaffirms 2026 target with IB Nimble 2 rollout
Imaging Biometrics (AIM:IBAI) confirmed it remains on track to make progress towards profitability in 2026, pairing the guidance update with the commercial launch of IB Nimble™ 2, its latest neuroimaging software product. The company is simultaneously expanding distribution for its broader software suite, signalling a push to widen its commercial footprint alongside the new release.
The combination of a reaffirmed financial target and a tangible product milestone lifted the shares 8.33% to 0.65p on the day.
Novo Nordisk brings Wegovy pill to UAE in global first
Novo Nordisk launched the oral version of its Wegovy weight-loss therapy in the United Arab Emirates, making the UAE the first country outside the United States to gain access to the GLP-1 pill formulation. The milestone extends the reach of the oral semaglutide programme beyond its initial market and positions the UAE as an early adopter of what has become one of the most closely watched drug classes in global medicine.
